Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Yahoo News
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based…
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirat…
-
Business19 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business18 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025
-
Noosa News15 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
Business15 hours ago1 ASX dividend stock down 43% I’d buy right now